Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature.

Denny AP, Heather AK.

Oxid Med Cell Longev. 2017;2017:7020295. doi: 10.1155/2017/7020295. Epub 2017 Jun 12. Review.

2.
3.

A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles.

Caron L, Kher D, Lee KL, McKernan R, Dumevska B, Hidalgo A, Li J, Yang H, Main H, Ferri G, Petek LM, Poellinger L, Miller DG, Gabellini D, Schmidt U.

Stem Cells Transl Med. 2016 Sep;5(9):1145-61. doi: 10.5966/sctm.2015-0224. Epub 2016 May 23.

4.

SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy.

Robin JD, Ludlow AT, Batten K, Gaillard MC, Stadler G, Magdinier F, Wright WE, Shay JW.

Genome Res. 2015 Dec;25(12):1781-90. doi: 10.1101/gr.190660.115. Epub 2015 Sep 10.

5.

DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy.

Thijssen PE, Balog J, Yao Z, Pham TP, Tawil R, Tapscott SJ, Van der Maarel SM.

Skelet Muscle. 2014 Oct 24;4:19. doi: 10.1186/2044-5040-4-19. eCollection 2014.

6.

FHL1 reduces dystrophy in transgenic mice overexpressing FSHD muscular dystrophy region gene 1 (FRG1).

Feeney SJ, McGrath MJ, Sriratana A, Gehrig SM, Lynch GS, D'Arcy CE, Price JT, McLean CA, Tupler R, Mitchell CA.

PLoS One. 2015 Feb 19;10(2):e0117665. doi: 10.1371/journal.pone.0117665. eCollection 2015.

7.

miRNA expression in control and FSHD fetal human muscle biopsies.

Portilho DM, Alves MR, Kratassiouk G, Roche S, Magdinier F, de Santana EC, Polesskaya A, Harel-Bellan A, Mouly V, Savino W, Butler-Browne G, Dumonceaux J.

PLoS One. 2015 Feb 18;10(2):e0116853. doi: 10.1371/journal.pone.0116853. eCollection 2015.

8.

β-Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy.

Banerji CR, Knopp P, Moyle LA, Severini S, Orrell RW, Teschendorff AE, Zammit PS.

J R Soc Interface. 2015 Jan 6;12(102):20140797.

9.

Next-generation sequencing analysis of miRNA expression in control and FSHD myogenesis.

Colangelo V, François S, Soldà G, Picco R, Roma F, Ginelli E, Meneveri R.

PLoS One. 2014 Oct 6;9(10):e108411. doi: 10.1371/journal.pone.0108411. eCollection 2014.

10.

Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes.

Dmitriev P, Kairov U, Robert T, Barat A, Lazar V, Carnac G, Laoudj-Chenivesse D, Vassetzky YS.

J Cell Mol Med. 2014 Feb;18(2):208-17. doi: 10.1111/jcmm.12182. Epub 2013 Dec 17.

11.

Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients.

Dmitriev P, Stankevicins L, Ansseau E, Petrov A, Barat A, Dessen P, Robert T, Turki A, Lazar V, Labourer E, Belayew A, Carnac G, Laoudj-Chenivesse D, Lipinski M, Vassetzky YS.

J Biol Chem. 2013 Dec 6;288(49):34989-5002. doi: 10.1074/jbc.M113.504522. Epub 2013 Oct 20.

12.

Altered expression of cyclin A 1 in muscle of patients with facioscapulohumeral muscle dystrophy (FSHD-1).

Pakula A, Schneider J, Janke J, Zacharias U, Schulz H, Hübner N, Mähler A, Spuler A, Spuler S, Carlier P, Boschmann M.

PLoS One. 2013 Sep 3;8(9):e73573. doi: 10.1371/journal.pone.0073573. eCollection 2013.

13.

DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.

Sharma V, Harafuji N, Belayew A, Chen YW.

PLoS One. 2013 May 22;8(5):e64691. doi: 10.1371/journal.pone.0064691. Print 2013.

14.

Members of the high mobility group B protein family are dynamically expressed in embryonic neural stem cells.

Abraham AB, Bronstein R, Chen EI, Koller A, Ronfani L, Maletic-Savatic M, Tsirka SE.

Proteome Sci. 2013 Apr 27;11(1):18. doi: 10.1186/1477-5956-11-18.

15.

miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors.

Harafuji N, Schneiderat P, Walter MC, Chen YW.

Orphanet J Rare Dis. 2013 Apr 5;8:55. doi: 10.1186/1750-1172-8-55.

16.

FSHD myotubes with different phenotypes exhibit distinct proteomes.

Tassin A, Leroy B, Laoudj-Chenivesse D, Wauters A, Vanderplanck C, Le Bihan MC, Coppée F, Wattiez R, Belayew A.

PLoS One. 2012;7(12):e51865. doi: 10.1371/journal.pone.0051865. Epub 2012 Dec 18.

17.

Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers.

Rahimov F, King OD, Leung DG, Bibat GM, Emerson CP Jr, Kunkel LM, Wagner KR.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16234-9. doi: 10.1073/pnas.1209508109. Epub 2012 Sep 17.

18.

Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD.

Krom YD, Dumonceaux J, Mamchaoui K, den Hamer B, Mariot V, Negroni E, Geng LN, Martin N, Tawil R, Tapscott SJ, van Engelen BG, Mouly V, Butler-Browne GS, van der Maarel SM.

Am J Pathol. 2012 Oct;181(4):1387-401. doi: 10.1016/j.ajpath.2012.07.007. Epub 2012 Aug 4.

19.

Deciphering transcription dysregulation in FSH muscular dystrophy.

Ehrlich M, Lacey M.

J Hum Genet. 2012 Aug;57(8):477-84. doi: 10.1038/jhg.2012.74. Epub 2012 Jun 21. Review.

20.

Gene expression during normal and FSHD myogenesis.

Tsumagari K, Chang SC, Lacey M, Baribault C, Chittur SV, Sowden J, Tawil R, Crawford GE, Ehrlich M.

BMC Med Genomics. 2011 Sep 27;4:67. doi: 10.1186/1755-8794-4-67.

Supplemental Content

Support Center